Haematologica (Mar 2009)
A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia
Abstract
No abstracts available.
Haematologica (Mar 2009)